Recordati Industria Chimica e Farmaceutica SPA stock analysis
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Share Price & Analysis
0KBS Stock Chart & Stats
- Day’s Range
- EUR 52.85 - EUR 52.90
- 52-Week Range
- EUR 43.78 - EUR 53.65
- Previous Close
- EUR 52.65
- Volume
- N/A
- Average Volume (3M)
- 54.11K
- Market Cap
- EUR 10.91B
- Enterprise Value
- EUR 12.60B
- Total Cash (Recent Filing)
- EUR 503.26M
- Total Debt (Recent Filing)
- EUR 2.21B
- Price to Earnings (P/E)
- 20.7
- Beta
- 0.67
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.54%
Bulls Say, Bears Say
Bulls Say
Strong Profitability
High gross, operating, and net margins indicate a profitable pharmaceutical model with meaningful earnings resilience. Sustained margin strength can support internal investment in medicines, commercial infrastructure, and portfolio development while providing protection against moderate revenue fluctuations.
Attractive Returns
A roughly 25% return on equity shows that Recordati is generating substantial earnings from its shareholder capital. If profitability remains durable, this level of capital efficiency can support reinvestment, strengthen shareholder returns, and reinforce the company’s financial quality.
Healthy Free Cash Flow
Free cash flow that covers about 90% of net income indicates that reported earnings are generally supported by cash generation. This improves the company’s ability to fund operations, invest in its portfolio, service obligations, and return capital without relying solely on external financing.
Bears Say
Slower Revenue Growth
The sharp slowdown in revenue growth reduces the pace at which Recordati can expand its earnings base and leverage its commercial platform. Even with resilient margins, prolonged low top-line growth could constrain operating leverage and increase reliance on portfolio execution.
Meaningful Leverage
Debt remains slightly above equity despite improving from prior years, leaving less balance-sheet flexibility than a lightly levered structure. Meaningful leverage can limit capacity for acquisitions, investment, or shareholder returns and makes financial planning more sensitive to cash-flow pressure.
Uneven Cash Conversion
Operating cash flow converting at about 46% of EBIT shows that cash realization is less consistent than the company’s accounting profitability. Historical free-cash-flow volatility can complicate funding plans and reduce confidence that strong margins will translate smoothly into deployable cash.
Recordati Industria Chimica e Farmaceutica SPA News
0KBS FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Robert Koremans
- Employees
- 4,693
- Website
- www.recordati.com
- Address
- Via Matteo Civitali,1, Milan, MI, 20148, IT
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 9 | 0 | 3 |









